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Abstract
A major goal for the treatment of patients with systemic lupus erythematosus with cytotoxic therapies is the induction of
long-term remission. There is, however, a paucity of information concerning the effects of these therapies on the
reconstituting B cell repertoire. Since there is recent evidence suggesting that B cell lymphopenia might attenuate negative
selection of autoreactive B cells, we elected to investigate the effects of cyclophosphamide on the selection of the re-
emerging B cell repertoire in wild type mice and transgenic mice that express the H chain of an anti-DNA antibody. The
reconstituting B cell repertoire in wild type mice contained an increased frequency of DNA-reactive B cells; in heavy chain
transgenic mice, the reconstituting repertoire was characterized by an increased frequency of mature, high affinity DNA-
reactive B cells and the mice expressed increased levels of serum anti-DNA antibodies. This coincided with a significant
increase in serum levels of BAFF. Treatment of transgene-expressing mice with a BAFF blocking agent or with DNase to
reduce exposure to autoantigen limited the expansion of high affinity DNA-reactive B cells during B cell reconstitution.
These studies suggest that during B cell reconstitution, not only is negative selection of high affinity DNA-reactive B cells
impaired by increased BAFF, but also that B cells escaping negative selection are positively selected by autoantigen. There
are significant implications for therapy.
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Introduction
Systemic lupus erythematosus (SLE) is a systemic autoimmune
disease characterized by the production of autoantibodies against a
vast array of self antigens, most notably double stranded (ds) DNA
[1]. Autoreactive B cells arise routinely in all individuals as a
consequence of the molecular processes that govern V gene
recombination and B cell receptor (BCR) diversification. In
healthy individuals, the B cell repertoire is purged of potentially
pathogenic autoreactive B cells at multiple developmental
checkpoints; however, in SLE patients, many of these checkpoints
are breached and autoreactive B cells become part of the mature,
immunocompetent and activated B cell repertoire [2–4].
A mainstay of lupus therapy for many decades has been
cyclophosphamide (CY), a cytotoxic agent that has been shown to
preferentially target B cells [5,6]. New therapies recently explored
for SLE include the use of the anti-CD20 antibody, which
selectively depletes B cells [7,8], as well as autologous hematopoi-
etic stem cell transplantation, which leads to both T and B cell
depletion. In each case, the underlying therapeutic strategy is to
permit the development of a reconstituted B cell repertoire devoid
of autoreactive B cells. It is clear that CY is beneficial in lupus
patients. Initial studies of human SLE patients and lupus-prone
mouse strains suggested that B cell depletion usually given together
with CY ameliorates disease activity in a subset of patients [9,10],
but two large randomized, placebo controlled studies of B cell
depletion with anti-CD20 antibody failed to show efficacy at 12
months. There remains a lack of critical information about how
autoreactive B cells reconstitute following B cell depletion,
especially in light of the observation that serum levels of BAFF
rise following B cell depletion [11] in an attempt to restore B cell
homeostasis. To begin to address this important issue, we studied
the effects of CY-induced B cell depletion on the selection of
DNA-reactive B cells in wild type (WT) BALB/c mice and in the
R4A Tg BALB/c mouse that expresses the heavy chain of a
pathogenic anti-DNA antibody. We demonstrate that during B
cell reconstitution, there is an increased maturation of high affinity
DNA-reactive B cells resulting in increased serum titers of anti-
DNA antibodies. A reduction in the elevated levels of BAFF that
result from B cell depletion or a decrease in antigen availability
diminished the expansion of these autoreactive B cells.
Results
Reconstitution of Splenic B Cell Subsets Following CY
Treatment
CY is a DNA alkylating agent that is cytotoxic to hematopoietic
cells, most notably B cells [5,6], and is commonly used to treat
PLoS ONE | www.plosone.org 1 January 2010 | Volume 5 | Issue 1 | e8418patients with lupus nephritis and neuropsychiatric lupus [12]. To
establish the kinetics of B cell reconstitution following a single dose
of CY (200 mg/kg of body weight), we first examined WT BALB/
c mice. As expected, CY-induced B cell depletion was almost
complete on day 3 with a greater than 95% reduction in splenic B
cells (Figure 1 A&B and Table 1). While CY treatment also
depleted T cells, T cell depletion was less extensive than B cell
depletion (Figure 1), confirming previous reports that B cells are
more susceptible to CY treatment [13].
Having established a dose of CY that induced near total B cell
depletion and partial T cell depletion, we determined the pattern
of B cell reconstitution. The absolute number of B cells in all
subsets increased substantially between days 3 and 14 (Figure 1A
and Table 2), there was a greater than 50% repopulation of
transitional T1 and T2 subsets, while the number of mature FO
and MZ B cells still lagged at this time point, such that total B cell
numbers were still reduced by 80% in CY-treated mice compared
to PBS-treated mice on day 14.
Figure 1. B cells following CY treatment. (A) B cell numbers following CY or PBS treatment. Flow cytometry was performed to identify B (B220
+)
cells and the Tg (IgG2b+) B cells. The B cell numbers from individual mice is represented. A significant decrease in total B cell numbers in both the
BALB/c WT mice as well as the BALB/c R4A Tg mice following CY treatment was observed at all time points analyzed, but was near normal by day 28.
(B) Lymphocyte numbers following CY or PBS treatment. Flow cytometry was performed to identify B (B220
+) cells and T (CD3
+) cells. A representative
dot plot is shown.
doi:10.1371/journal.pone.0008418.g001
B Cell Depletion
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mice increased to greater than 60% of that in PBS-treated mice;
FO and MZ B cell numbers increased to 50% of levels in PBS-
treated mice, demonstrating that during this period, restoration of
mature splenic B cell compartments was occurring (Table 2 and
Figure 2). Taken together, these data indicate that significant
reconstitution of mature B cell subsets takes place over a span of
approximately 28 days after the existing B cell populations are
depleted by a single dose of CY, and are in agreement with
previous studies suggesting that B cell numbers return to near
normal levels within a month after CY treatment [6].
To understand the antigenic specificity of the reconstituting B
cell repertoire, we chose to enumerate DNA-reactive B cells. On
day 14, we examined the repertoire in WT mice by DNA-specific
IgG ELISpot assay. CY-treated mice had a significantly higher
frequency of B cells spontaneously secreting anti-DNA antibody
than PBS-treated mice (Figure 3). Thus, the reconstituting B cell
repertoire was enriched for activated DNA-reactive B cells.
Expansion of High Affinity DNA Reactive B Cells during
Reconstitution in CY-Treated R4A Tg Mice
Since the primary purpose of this study was to determine the
effects of CY-induced B cell depletion on the reconstitution of the
B cell repertoire of a lupus patient,, we decided to continue our
studies using the R4A Tg mouse that expresses the IgG2b heavy
chain of the R4A anti-DNA antibody. Most transgene expressing
B cells are allelically excluded and express a non-DNA binding
antibody or a low affinity DNA binding antibody and display a
normal maturational program. There is small number of allelically
included (IgM and IgG2b) anergic B cells that express an IgG2b
anti-DNA antibody and an IgM antibody that is not DNA-
reactive. These cells can only be detected by fusion of LPS-
stimulated splenic B cells. We have previously shown that the high
affinity DNA-reactive B cells are deleted at both the immature to
transitional and transitional to mature stages. Tolerance induction
of low affinity DNA-reactive B cells occurs only at the immature to
transitional stage. Thus, B cell tolerance is maintained in R4A Tg
BALB/c mice and the mice do not express elevated serum titers of
anti-DNA antibody despite the enforced expression of the
transgenic anti-DNA heavy chain in about 5–10% of B cells.
The majority of B cells express an endogenous IgM BCR, allowing
for normal competition among B cells for survival niches [14]. On
day 3 after CY treatment, R4A Tg-BALB/c mice displayed a
greater than 95% loss of splenic B cells, and thereafter mice
exhibited a pattern of B cell reconstitution similar to that exhibited
by WT BALB/c mice (Table 3 and Figure 1A). The effect of CY
treatment on the reconstitution of Tg
+ (B220
+/IgG2b
+) B cells was
also determined (Table 4 and Figure 1A). Transgene-expressing B
cells of R4A BALB/c mice were reduced on day 3 following CY
treatment by greater than 90%. The reconstitution of Tg
+ B cells
compared to Tg
2 B cells was slightly although not significantly
more rapid, resulting in an increased relative frequency of Tg
+ B
cells during reconstitution.
Our previous analysis of hybridomas from R4A Tg BALB/c
have allowed us to identify germline-encoded light chains which,
when paired with the R4A heavy chain, give rise to high affinity
DNA-reactive B cells. Previously, we have demonstrated that the
pairing of the R4A heavy chain with either germline-encoded
Vk1A-Jk1o rV k1A-Jk4 light chains generates an antibody with
high affinity for DNA [15]. Usually, these cells are tolerized, and
eliminated during the early stages of selection [16,17]. To analyze
the frequency of high affinity DNA-reactive B cells within the
reconstituting repertoire, individual Tg
+ B cells from 3 individual
mice were isolated and single cell RT-PCR and sequence analysis
was performed. Tg
+ B cells were first analyzed to confirm that they
expressed a c2b heavy chain. We also examined Tg
+ B cells for
expression of a m heavy chain to ensure that we were not seeing a
preferential increase in survival of allelically included B cells. Of 15
Tg
+ B cells isolated by single cell sorting, 14 expressed a c2b heavy
chain; none expressed a m heavy chain (data not shown). Thus, the
cells we studied maintained allelic exclusion. The frequency of
mature Tg
+ B cells utilizing light chains that generate a high
affinity anti-DNA antibody was determined. On day 14 the
frequency of high affinity DNA-reactive transitional and mature
Tg
+ B cells that were present in CY-treated mice was significantly
increased compared to PBS-treated R4A Tg mice (Table 5),
indicating that more potentially pathogenic autoreactive B cells
bypassed the stages of negative selection in both bone marrow and
spleen during reconstitution and entered in the immunocompetent
repertoire. Interestingly, on day 28, the frequency of transitional
and mature high affinity DNA-reactive B cells was still increased in
CY-treated R4A Tg mice; there was a decrease of nearly 50%
when compared with day 14, although this difference was not
statistically significant (data not shown). These data demonstrate
that negative selection was altered in the reconstituting B cells
repertoire as there were more high affinity DNA-reactive B cells in
the transitional and mature B cell compartments.
Elevation in BAFF Following CY Treatment
BAFF has emerged as a crucial factor that modulates B cell
survival and development [18] and is required for the stages of B
cell maturation beyond the T1 stage and for the maintenance of
FO and MZ B cells [19–21]. There are also data to suggest that
autoreactive B cells require more BAFF than non-autoreactive B
cells for survival and excess BAFF can rescue anergic autoreactive
B cells when there is a reduced number of naı ¨ve, competitor B cells
[22]. It is now established that B cell depletion in humans leads to
Table 1. Absolute number and percentages of splenic B cells
and T cells on day 3.
Treatment B cells (610
5) B cells (%) T cells (610
5) T cells (%)
PBS 193 (634) 49.4 (63.3) 146.0 (623.6) 41.0 (65.4)
CY 8.3* (62.3) 5.4 (61.8) 35* (67.7) 81.4 (61.9)




Table 2. Percentage of splenic B cells during reconstitution.
Transitional B cells Mature B cells
T1 T2 FO MZ
Day 3 PBS 24.9 (63.1) 13.7 (62.2) 54.8 (69.2) 5.6 (60.7)
CY 27.6(67.3) 15.6(60.01) 29.6* (60.05) 18.6* (64.7)
Day 14 PBS 19.5 (62.1) 10.8 (62.1) 59 (69.2) 4. 2 (61.3)
CY 50.1* (69.8) 29.9* (66.0) 20.4* (67.8) 4.5 (60.01)
Day 28 PBS 12.6 (62.7) 10.6 (61.4) 62.9 (612.4) 12.9 (61.7)
CY 12.4(60.04) 19.8* (62.8) 63.8 (68.3) 5* (61.8)
n=5 mice per group. Data are presented as the mean6SD.
*denotes that the comparison of PBS to CY-treated mice was p,0.001.
doi:10.1371/journal.pone.0008418.t002
B Cell Depletion
PLoS ONE | www.plosone.org 3 January 2010 | Volume 5 | Issue 1 | e8418a rise in serum levels of BAFF [11]. To determine the effects of CY
treatment on circulating BAFF levels, serum was obtained from
both WT and R4A Tg mice before and after treatment and BAFF
levels were quantified by ELISA. In both CY-treated WT BALB/c
and R4A Tg BALB/c mice, a significant elevation in BAFF was
observed (Figure 4 and data not shown). While the increase in
BAFF peaked by day 5, BAFF levels remained significantly
increased until day 21 following CY treatment. Thus, these data
indicate that serum BAFF levels are markedly elevated during B
cell reconstitution.
BAFF Neutralization Prevented the Accumulation of High
Affinity DNA-Reactive B Cells in the Reconstituting
Repertoire
The expansion and escape from normal mechanisms of B cell
tolerance of high affinity DNA-reactive B cells during B cell
reconstitution strongly suggests positive selection of this BCR
specificity. To understand the mechanism(s) for the change in B
cell selection, we focused on the role of BAFF and autoantigen in
the reconstituting repertoire. BAFF is a critical B cell survival
factor and BAFF levels have been shown to rise in autoimmune
patients following B cell depletion [11,23]. It has been shown
experimentally that increasing the levels of BAFF in a B cell
depleted environment can promote the survival of autoreactive B
cells that would normally be silenced [22]. We, therefore, assessed
the effects of BAFF neutralization on B cell reconstitution and the
Figure 3. ELISpot assay to enumerate the DNA-reactive B cells.
Five BALB/c mice were treated with CY and five with PBS. Student’s t
test was used to determine the significance between the groups. A
significant increase in the DNA-reactive cells was observed in CY-treated
mice (p,0.05).
doi:10.1371/journal.pone.0008418.g003
Figure 2. Splenic B cell populations following CY or PBS treatment. The markers B220 and AA4.1 were used to differentiate mature (B220
+/
AA4.1
2) and transitional (B220
+/AA4.1





pos) populations and the transitional gate was used to identify T1 (CD21
neg/HSA
hi) and T2 (CD21
pos/HSA
hi) subsets. Five mice were
analyzed at each time point. Representative data are shown. The absolute numbers are presented in Table 2.
doi:10.1371/journal.pone.0008418.g002
Table 3. Percentage of splenic B cells of R4A Tg mice
following treatment with CY.
Transitional B cells Mature B cells
T1 T2 FO MZ
Day 3 PBS 8.3 (62.7) 5.3 (61.6) 49.7 (69.2) 25.3 (69.7)
CY 13.7* (65.2) 7.7(63.3) 14.2* (65.0) 42.5*(67.8)
Day 14 PBS 15.2 (64.3) 8.8 (62.5) 48 (66.9) 14.7 (63.5)
CY 31.5* (65.9) 21* (63.8) 27.7* (67.5) 11.3 (66.7)
Day 28 PBS 8.5 (62.3) 9.5 (61.0) 47.7 (614.6) 26.9 (68.5)
CY 5.0* (61.0) 9.9 (64.8) 57.5 (69.5) 17.3 (67.6)
n=4–5 mice per group. Data are presented as the mean6SD.
*denotes that the comparison of PBS to CY-treated mice was p,0.001.
doi:10.1371/journal.pone.0008418.t003
B Cell Depletion
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induced B cell depletion. R4A Tg mice were given recombinant
BAFF-R-Ig as previously described beginning 3 days after CY
administration [24]. BAFF-R-Ig treatment resulted in an accu-
mulation of transitional T1 B cells on day 14 (data not shown), as
expected, since BAFF is required for maturation to the transitional
T2 stage [20]. In addition, neutralization of BAFF resulted in a
decrease in MZ B cells, which is also in agreement with previous
studies indicating the sensitivity of this B cell subset to changes in
BAFF levels [19]. Neutralization of BAFF with BAFF-R-Ig
reduced the frequency of immature and mature high affinity
DNA-reactive B cells to that present in PBS-treated mice (Table 6),
indicating that the emergence of high affinity-DNA reactive B cells
into the transitional and then mature B cell repertoire may be due,
at least in part, to the increased serum concentration of BAFF in
the lymphopenic host.
DNase Treatment Blocks Maturation of High Affinity
DNA-Reactive B Cells
DNase treatment of B/W F1 mice has been shown to reduce
anti-DNA antibody titers, but there are conflicting data regarding
the efficacy of DNase treatment on glomeruloneprhritis and
survival [25,26]. Presumably the reduced production of anti-DNA
antibodies reflects a lower amount of DNA to drive the expansion
of DNA-reactive B cells.
While it has not been conclusively demonstrated that DNA itself
is the eliciting antigen that drives the selection and expansion of
DNA-reactive B cells, CY induces massive cell death augmenting
the antigenic load potentially capable of stimulating DNA-reactive
B cells. We, therefore, asked whether DNase might reduce the
expansion of DNA-reactive B cells. We reasoned that DNase-
treatment would decrease DNA levels in CY-treated mice, and
thus limit the positive selection of high affinity DNA-reactive B
cells. Beginning 4 days after R4A mice were given CY, daily
injections of active or heat-inactivated DNase were administered
for 14 days. Analysis of the DNA-reactive repertoire revealed that
the expansion of high affinity DNA-reactive B cells that was
observed in CY-treated mice was diminished by administration of
active DNase but not by heat-inactivated DNase (Table 7). This
was discernable in both the transitional and mature B cell
populations, suggesting that the positive selection of autoreactive B
cells by antigen begins at the transitional stage of development.
Anti-DNA Antibody Titers Following CY Treatment
In order to determine if the CY-induced skewing of the
reconstituting B cell repertoire toward autoreactivity was of
consequence, we assayed for anti-DNA antibodies in the serum.
CY-treated R4A Tg mice displayed higher titers of anti-DNA
Table 6. Frequency of high affinity DNA-reactive B cells in
R4A Tg mice treated with CY and BAFF-R-Ig.
PBS CY CY+BAFF-R-Ig
Transitional 5/65 (8%) 16/60 (27%)* 3/60 (5%)
Mature 5/64 (8%) 25/70 (36%)* 4/59 (7%)
Data are presented as the frequency of Tg+ B cells expressing Vk1a/Jk1 or Jk4
out of the total number of B cells examined. The percentages are shown in
parenthesis. There was an increase in high affinity DNA-reactive B cells in CY vs
PBS-treated mice (*p,0.01), but not in CY+BAFF-R-Ig treated mice.
doi:10.1371/journal.pone.0008418.t006
Table 4. Percentage of IgG2b+ B cells of R4A Tg mice
following treatment with CY.
Transitional B cells Mature B cells
T1 T2 FO MZ
Day 3 PBS 13.0 (61.0) 7.8 (61.0) 33.0(62.3) 37.4 (64.2)
CY 15.4(63.0) 7.7 (61.5) 23.1* (66.9) 46.0 (67.7)
Day 14 PBS 16.7 (66.5) 13.5 (61.7) 34.1 (65.6) 30.2 (64.0)
CY 12.8 (62.2) 8.4* (61.0) 37.2 (64.2) 32.8 (63.7)
Day 28 PBS 15.1 (62.3) 12.3 (61.8) 37.8 (67.3) 34.0 (64.5)
CY 11.2 (62.7) 13.7 (62.1) 33.3 (65.0) 37.3 (67.2)
n=4–5 mice per group. Data are presented as the mean6SD.
Tg+ B cells were reconstituted in all subsets by day 28. They were significantly
reduced in CY-treated mice prior to that time.
*p,0.01.
doi:10.1371/journal.pone.0008418.t004
Table 5. Frequency of high affinity DNA-reactive B cells in CY-
treated R4A Tg mice.
PBS CY
Transitional 4/55 (7.3%) 16/65 (24.4%)*
Mature 3/60 (5%) 20/71 (28.2%)*
Data are presented as the frequency of Tg+ B cells expressing Vk1a/Jk1 or Jk4
out of the total number of B cells examined in PBS and CY-treated R4A Tg mice.
The percentages are shown in parenthesis. CY-treated mice showed a higher
frequency in both the transitional and mature subsets (*p,0.02).
doi:10.1371/journal.pone.0008418.t005
Figure 4. Elevation of serum BAFF during B cell reconstitution.
Serum BAFF levels in five mice were measured by ELISA following
administration of CY. BAFF was significantly elevated following 3 days
after CY treatment and remained elevated until day 28. *p,0.01 as
determined by Mann-Whitney test.
doi:10.1371/journal.pone.0008418.g004
B Cell Depletion
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Furthermore, both BAFF-R-Ig and active DNase, but not heat-
killed DNase, led to reduced serum titers of anti-DNA antibody
(Figure 5A & 5B). Moreover, glomerular Ig depostion was present
in CY-treated mice but not observed in CY-treated mice
administered BAFF-R-Ig or active DNase (Figure 5B). Thus,
serum DNA reactivity and glomerular Ig deposition confirmed the
findings of the repertoire analysis.
Discussion
The data reported here demonstrate that the eradication of a B
cell repertoire may result in the selective expansion of autoreactive
B cells and increased autoantibody production. In the WT host,
there was a specific expansion of DNA-reactive B cells during B
cell reconstitution. We believe this phenomenon might contribute
to clinical relapse in patients with SLE. Indeed, these data support
a recent clinical study which demonstrated that a subset of lupus
patients treated with CY developed anti-phospholipid antibodies
and anti-phospholipid syndrome following therapy [27]. They also
support a study which analyzed kappa and lambda light chain
usage during B cell reconstitution after treatment with rituximab, a
B cell depleting antibody, and demonstrated a shift in B cell
repertoire toward an increased kappa/lambda ratio [23]. It is
noteworthy that in WT non-autoimmune BALB/c mice, the B cell
reconstitution phase led to a mature B cell repertoire with a higher
frequency of potentially pathogenic DNA-reactive B cells, but no
frank serologic autoreactivity. In contrast, in the R4A Tg mouse,
predisposed to have enhanced survival of autoreactive B cells, B
cell reconstitution was accompanied by autoimmune features
including elevated serum titers of autoantibodies and glomerular
immunoglobulin deposition. We believe this mirrors the situation
in patients with SLE, who are predisposed to a decreased
stringency of negative selection, perhaps by virtue of expression
of the susceptibility allele of PTPN22 and/or Blk [28]. It is also
important to note that elevated BAFF has previously shown to
decrease the negative selection of DNA-reactive B cells in mice,
although in that study the enhanced BAFF levels were not induced
by lymphopenia, and there was no increase in autoantibody titers
[29]. We believe this may reflect a difference in fine specificity or
affinity of the transgene-encoded anti-DNA antibody such that
there was less positive selection.
It is possible that the rise in autoantibody titers that we observe
following B cell reconstitution in R4A Tg mice may be transient
and at a later time point, the high affinity DNA-reactive B cell
population might contract in size as the proportion of non-
autoreactive competitor B cells increases. While it is plausible that
these potentially pathogenic B cells have a limited time frame in
which they can undergo activation, our data indicate that mature
high affinity DNA-reactive B cells that are expanded during B cell
reconstitution remain part of the naı ¨ve repertoire for at least 1
month and can be activated to secrete autoantibody. We believe
that once the titers of DNA-reactive antibodies rise, the immune
complexes they form activate toll-like receptor 9 (TLR 9) in
dendritic cells to increase production of BAFF and proinflamma-
tory cytokines and to transform the dendritic cells from a
tolerogenic to an immunogenic state. The same DNA containing
immune complexes may activate TLR 9 in DNA-reactive B cells
to promote their survival through tolerance checkpoints and to
help them class switch to production of the proinflammatory IgG
isotype.
The reduction in frequency of high affinity DNA-reactive B cells
by treatment with DNase supports a role for antigen in the
expansion of these cells after CY exposure. CY treatment increases
the concentration of extracellular DNA levels due to the large
amount of cell death, so it seems logical to surmise that DNAse
may reduce the local concentration of DNA in the spleen and thus,
impair the autoantigen-mediated expansion of high affinity DNA-
reactive B cells.
In light of the findings that BAFF is elevated in SLE and greatly
elevated following B cell depletion and the recent failure of anti-
CD20 antibody, a B cell depleting antibody to demonstrate clinical
efficacy in the treatment of SLE despite successful B cell depletion,
our data suggest that B cell depletion may only be effective if the
re-emergence of high affinity autoreactive B cells can be kept in
check. In fact, we are concerned that all B cell depleting therapies,
whether or not there is an accompanying T cell depletion, may
promote the expansion of high affinity autoreactive B cells during
B cell reconstitution. This is in keeping with several studies
suggesting that high affinity autoreactive B cells have a survival
advantage in the absence of a diverse repertoire of competitor B
cells [30,31]. Thus, agents that transiently reduce B cell number
may ultimately enhance the survival of potentially pathogenic B
cells. Furthermore, the increased BAFF may trigger heavy chain
class-switching independent of T cell help and so enhance the
pathogenicity of autoantibodies [32]. It is of interest to note that
BAFF blockade with an anti-BAFF antibody has just been
reported to reduce anti-DNA antibody levels and disease activity
in a Phase III study in lupus patients. This therapy causes a mild
reduction in B cells, but may limit the survival and maturation of
newly minted autoreactive B cells. It will be interesting to
determine if it indeed leads to a less autoreactive B cell repertoire.
We are aware that the expansion of high affinity DNA-reactive
B cells after CY treatment may not be a consequence of BAFF
levels and antigen availability only. There are studies suggesting
that the re-emergence of Tregs may be delayed following CY
treatment [33]. While our data do not exclude the possibility that a
diminished Treg compartment may contribute to the increased
maturation of autoreactive B cells, a role for Tregs during selection
of the naı ¨ve repertoire has not been clearly established.
In conclusion, we demonstrate that expansion of autoreactive B
cells occurred following B cell depletion, and BAFF and
autoantigen both may play an important role in the enhanced
selection of high affinity autoreactive B cells during B cell
reconstitution. Our findings raise some critical issues about the
therapeutic use of B cell depleting agents and provide a rationale
for the use of BAFF blockade during B cell reconstitution to
diminish the survival of potentially pathogenic B cells.
Materials and Methods
Ethics Statement
Mice were housed in an Association for Assessment and
Accreditation of Laboratory Animal Care (AAALAC) approved
Table 7. Frequency of high affinity DNA-reactive B cells in
R4A Tg mice treated with CY and DNase.
PBS CY CY+DNase CY+HI-DNase
Transitional 7/65 (10%) 11/52 (21%)* 5/62 (8%) 13/65 (20%)*
Mature 4/70 (6%) 14/57 (25%)* 5/50 (10%) 16/70 (23%)*
Data are presented as the frequency of Transgene-positive B cells expressing
Vk1a/Jk1 or Jk4 out of the total number of B cells examined. The percentages
are shown in parenthesis. There was a significant increase in CY and CY+HI-
DNase vs PBS treated mice (*p,0.01), but not in CY+DNase treated mice.
doi:10.1371/journal.pone.0008418.t007
B Cell Depletion
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Animal Care and Use Committee (IACUC) approved protocols.
Mice and Therapeutic Regimens
BALB/c mice were purchased from Jackson Laboratory (Bar
Harbor, ME). R4A BALB/c mice have been described previously
[14]. Eight to 12 week-old mice were used for all studies. Mice
were housed in a specific pathogen-free facility and animal studies
were approved by the Institutional Animal Care and Use
Committee at the Feinstein Institute for Medical Research. CY
(Cytoxan, Bristol-Meyers Squibb) was dissolved in sterile pyrogen-
free PBS and 200 mg/kg body weight was given i.p. Control mice
received PBS. Recombinant murine BAFF-receptor-Fc fusion
protein (BAFF-R-Ig) was generated as previously described [23].
Beginning 3 days after administration of CY, R4A Tg mice were
given 300 mg of BAFF-R-Ig twice a week for 2 or 5 weeks. DNase
(450 mg in 200 ml saline) or heat-inactivated DNase (68uC for
15 minutes) (Sigma) was given ip every day for 2 or 5 weeks
beginning on day 4 following CY treatment.
Flow Cytometry
Splenocytes isolated from PBS- and CY-treated mice were
stained with fluorochrome-labeled antibodies specific for CD21/
CD35, CD23, CD3, CD4, CD8, B220, IgG2b (BD Pharmingen),
Figure 5. Increase in serum anti-dsDNA antibodies following CY exposure. (A) Serum anti-dsDNA antibodies levels in R4A Tg mice
following exposure to CY, CY+BAFF-R-Ig, CY+DNase or CY+heat-inactivated DNase (n=5 mice in each group). A significant increase in dsDNA-reactive
antibodies was observed in the serum of CY-treated R4A Tg mice (p,0.003) that was decreased upon treatment wth BAFF-R-Ig (p,0.02) or with
active DNase (p,0.01) but not with heat-inactivated DNase. The statistical significance between the groups was determined by paired t test. (B)
Glomerular Ig deposition in R4A Tg mice following administration of CY, CY+BAFF-R-Ig or CY+DNase. Ig depostion was observed in CY-treated R4A
mice and was diminished upon additional treatment with BAFF-R-Ig or with active DNase. Five mice in each group was used for these studies.
doi:10.1371/journal.pone.0008418.g005
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Biotech) at 4uC for 30 minutes. Biotinylated mouse IgG2b was
detected using streptavidin-conjugated fluorochrome (BD Phar-
mingen). The cells were then washed with PBS and analyzed by
flow cytometry using an LSRII instrument (BD Biosciences) and
the data were analyzed using Flowjo software (Tree star).
Single Cell RT-PCR and Repertoire Analysis
Splenocytes from PBS- or CY-treated R4A mice (3 per
condition) were stained with antibodies specific for B220, IgG2b
and AA4.1 and B220
+/Tg
+/AA4.1
2 cells were individually sorted
into 96-well plates using a FACSAria (BD Biosciences). Single-cell
RT-PCR was performed as described previously [4], using the
following primers: universal Vk:5 9GGCTGCAGSTTCAGTGG-
CAGTGGRTCWGGRAC39+constant region primer (Ck)( 1
st
round): 59TGGATGGGTGGGAAGATG39 and Ck (2
nd round);
59AAGATGGATACAGTTGGT39. PCR products were subject-
ed to exo-SAP treatment (USB Biochemicals) and automated
sequencing was performed using the 2
nd round Ck primer
(Genewiz Inc., NJ). To confirm heavy chain allelic exclusion in
transgene-expressing B cells, PCR of m constant region was also
performed with the following primers: R4A VH primer
CTGCAACCGGTGAGGTGAAGCTGGTGGA ATCTG and
the m constant region primers CAGGGGGCTCTCGCAGGA-
GACGAGG (1
st round) and GGGATCCTGGGAAGGACT
GACTCTC (2
nd round).
Measurement of Serum BAFF
The concentration of soluble BAFF was determined by ELISA.
96-well plates were coated with 5 mg/ml of anti-mouse BAFF mAb
(clone 5A8; Apotech). After blocking with 5% BSA, serial dilutions
of mouse serum or mouse recombinant BAFF (Apotech) were
added to the wells, followed by 10 mg/ml of biotinylated
monoclonal anti-mouse BAFF antibody (clone 1C9; Apotech)
and HRP-labeled streptavidin. Optical density was measured at
450 nm.
Anti-dsDNA ELISA
Sera from PBS- or CY-treated BALB/C mice and from R4A
mice treated with PBS, CY, CY+BAFF-R-Ig, CY+DNase or
CY+heat inactivated DNase (n=5 in each group) were diluted
1:100 and assayed for IgG2b anti-dsDNA antibodies as previously
described [2].
ELISpot Assay
Five BALB/c mice were treated with CY and five with PBS.
Splenocytes isolated from these mice were added in serial dilution
to DNA-coated plates and incubated for 12 hours at 37uC. Biotin-
conjugated goat anti-mouse IgG (Southern Biotechnology) diluted
1:600 was added, followed by alkaline phosphatase-conjugated
streptavidin (Southern Biotechnology) at 1:1000 dilution. The
plates were developed with 5-bromo-4-chloro-3 indolyl phosphate
substrate (Sigma-Aldrich). DNA-reactive spots were counted
under a dissecting microscope.
Renal Pathology
Kidneys from R4A Tg mice treated with PBS, CY, CY+BAFF-
R-Ig and CY+DNase were fixed in formalin. The fixed tissues
were paraffin-embedded, sectioned (10 micron thickness) and
stained with biotinylated anti-mouse IgG and developed with
alkaline phosphatase ABC detection kit (Vector Laboratories).
Glomerular IgG deposition in the kidney sections was visualized
under a Zeiss microscope using the Axiovision software. Five mice
in each group were used for these studies.
Statistical Analysis
Statistical analysis was performed using Fishers’s exact test,
Student’s t test and Mann-Whitney Test as indicated in the text. A
p value of ,0.05 was considered to be statistically significant.
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